Jurisdiction - China
Skadden Advises 3SBio Listing In Hong Kong.

11 June, 2015


Skadden advised 3SBio, Inc. on its HKD 5.52bn (approximately USD 712m) public offering on the Hong Kong Stock Exchange. The listing was announced on 1 June and shares began trading on 11 June.  The Hong Kong public offer was more than 200 times oversubscribed.


Shenyang-based 3SBio, Inc. is a Chinese biotechnology company, producing pharmaceuticals to treat blood disorders and to counteract the side effects of chemotherapy. 


Skadden’s lead partners were Peter Huang, Christopher Betts and Will Cai.


Conventus Law

Follow us on Twitter @conventuslaw

Comments are closed.